# Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

> **NCT05075603** · PHASE1 · COMPLETED · sponsor: **NeoImmuneTech** · enrollment: 17 (actual)

## Conditions studied

- Refractory Diffuse Large B-cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory High Grade B-Cell Lymphoma
- Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Efineptakin alfa
- **DRUG:** Tisagenlecleucel
- **DRUG:** Axicabtagene ciloleucel
- **DRUG:** Lisocabtagene Maraleucel

## Key facts

- **NCT ID:** NCT05075603
- **Lead sponsor:** NeoImmuneTech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-06
- **Primary completion:** 2024-12-18
- **Final completion:** 2025-03-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05075603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05075603, "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05075603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*